EP1240176A1 - Benzophenonglycopyranosiden, herstellung und therapeutische verwendung - Google Patents

Benzophenonglycopyranosiden, herstellung und therapeutische verwendung

Info

Publication number
EP1240176A1
EP1240176A1 EP00988884A EP00988884A EP1240176A1 EP 1240176 A1 EP1240176 A1 EP 1240176A1 EP 00988884 A EP00988884 A EP 00988884A EP 00988884 A EP00988884 A EP 00988884A EP 1240176 A1 EP1240176 A1 EP 1240176A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
group
tetraacetyl
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00988884A
Other languages
English (en)
French (fr)
Inventor
Luc Lebreton
Christiane Legendre
Soth Samreth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Fournier Industrie et Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Industrie et Sante SAS filed Critical Fournier Industrie et Sante SAS
Publication of EP1240176A1 publication Critical patent/EP1240176A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Definitions

  • the present invention relates, as new industrial products, to 4-cyano-4'-hydroxybenzophenone derivatives of formula I below which are benzophenone glycopyranosides. It also relates to their preparation process as well as their use in therapy, in particular in the form of compositions containing them as active principles.
  • EP-A-0051023 compounds having a hydroxybenzophenone residue substituted with a ⁇ -D-xylosyl group, and having an advantageous pharmacological activity for treating or preventing venous thrombosis.
  • EP-A-0133103 Also known from EP-A-0133103 are derivatives of the benzylphenyl ⁇ -D-xyloside type endowed with cholesterol-lowering and lipid-lowering properties. It is also known that in EP-A-0365397, EP-A-0290321, derivatives have been described in which the ⁇ -D-xylosyl radical has been replaced by a ⁇ -D-thioxylosyl radical, said compounds being useful because of their antithrombotic activity.
  • This mode of action obtained after administration of the product by the oral route, is very probably responsible for the antithrombotic activity and only the derivatives of the ⁇ configuration of D-xylose exhibit activity in this therapeutic field. There is therefore a correlation between the action on the synthesis GAGs and the antithrombotic activity which made the compounds other than those derived from ⁇ -D-xylose irrelevant in this therapeutic area.
  • new products are recommended, which are characterized in that they are chosen from the group consisting of:
  • glycopyranosyl group R represents a ⁇ -D-arabinopyranosyl, ⁇ -D-lyxopyranosyl, ⁇ -D-ribopyranosyl, ⁇ -D- galactopyranosyl, ⁇ -D-mannopyranosyl, ⁇ -L-arabinopyranosyl, ⁇ - L-xylopyranosyl group , ⁇ -L-arabinopyranosyle, ⁇ -L-xylopyranosyle or ⁇ - L-rhamnopyranosyle; and, (ii) their esters resulting from the esterification of at least one OH function of each glycopyranosyl group with a C 2 -C alkanoic or cycloalkanoic acid.
  • a process for preparing the compounds of formula I above and their esters there is provided a process for preparing the compounds of formula I above and their esters.
  • a therapeutic composition is provided, characterized in that it contains, in association with a physiologically acceptable excipient, an amount therapeutically effective of at least one compound of formula I or of one of its esters.
  • the use of a compound of formula I or of one of its esters is also recommended as an active principle for obtaining a medicament intended for use in therapeutic vis -in relation to the atheroma plaque, in particular for the prevention or treatment thereof.
  • the new compounds according to the invention include the products of formula I and their esters; they are pyranoside derivatives of 4-cyano-4 '-hydroxybenzophenone [or 4- (4-hydroxybenzoyl) benzonitrile].
  • the preferred products, in which the glycoside radical is in pyranose form correspond to the following formulas given as a function of the structure of the glycopyranosyl group R: (a) ⁇ -D-arabinose structure ( ⁇ -D-Ara):
  • R 1 represents a hydrogen atom or a COR 2 group, R 2 being a C 1 -C 3 alkyl group chosen from methyl, ethyl, propyl, isopropyl and cyclopropyl groups.
  • the process for the preparation of a compound of formula I or of one of its esters according to the invention is characterized in that it comprises: (1 °) the reaction of a peracetylated pentose or hexose of pyranosyl structure, corresponding in formula II:
  • Z is H, CH 3 or CH 2 OAc, and chosen from the group consisting of 1,2,3,4-tetraacetyl-D-arabinose, 1,2,3,4-tetraacetyl-D-lyxose, 1 , 2,3,4-tetraacetyl-D-ribose, 1,2,3,4,6-pentaacetyl-D-galactose, 1,2,3,4,6-pentaacetyl-D-mannose, 1,2,3 , 4-tetraacetyl-L-arabinose, 1,2,3,4-tetraacetyl-L-xylose and 1,2,3,4-tetraacetyl-L-rhamnose, with 4- (4-hydroxybenzoyl) benzonitrile of formula III
  • reaction II + III of step (1 °) is carried out in an organic solvent, (in particular dichloromethane), in the presence of a Lewis acid (such as for example tin tetrachloride), at a temperature between 25 ° C and the boiling point of the solvent, for 10 to 30 hours.
  • organic solvent in particular dichloromethane
  • Lewis acid such as for example tin tetrachloride
  • step (2 °) the replacement of the Ac groups by hydrogen atoms is advantageously carried out as follows.
  • the compound of formula IN is reacted with ⁇ H 3 in solution in an anhydrous alcohol (in particular methanol) to displace the Ac groups and replace them with H.
  • an anhydrous alcohol in particular methanol
  • step (1 °) becomes the following step (1 '), namely:
  • X is a halogen atom (ie F, Cl, Br or I, the preferred halogen atom being Br) and Z is H, CH 3 or CH 2 OAc, and chosen from the group consisting of l -bromo-2,3,4-triacetyl-D- arabinose, 1 -bromo-2,3, 4-triacetyl-D-lyxose, 1 -bromo-2,3, 4-triacetyl- D-ribose, l-bromo -2,3,4,6-tetraacetyl-D-galactose, 1-bromo-2,3,4,6- tetraacetyl-D-mannose, 1 -bromo-2,3,4-triacetyl-L-arabinose, 1 -bromo-2,3,4-triacetyl-L-xylose, and l-bromo-2,3,4-triacetyl-L-rhamnose, with 4- (4-hydroxybenzo
  • the N + III - IN reaction is carried out in an anhydrous solvent such as dichloromethane, 1-2-dichloroethane or acetonitrile, in the presence of a coupling agent such as silver trifluoromethanesulfonate or the silver oxide, at a temperature of the order of -10 to + 10 ° C, for 5 to 40 hours.
  • anhydrous solvent such as dichloromethane, 1-2-dichloroethane or acetonitrile
  • a coupling agent such as silver trifluoromethanesulfonate or the silver oxide
  • Example 1 [4- [4-cyanobenzoyl) phenyl] 2,3,4-tri-O-acetyl- ⁇ -D-arabinopyranoside
  • a solution of 0.8 g (2.52 ⁇ 10 ⁇ 3 mole) of 1.2 is prepared , 3,4-tetra-O-acetyl-D-arabinopyranose and 0.567 g (2.52.10 "3 mole) of 4- (4-hydroxybenzoyl) benzonitrile in 15 ml of anhydrous dichloromethane.
  • a mixture of 90 mg (0.19 ⁇ 10 ⁇ 3 mole) of the compound obtained according to Example 1 is prepared in 20 ml of a solution of 2M ammonia in methanol and the mixture is stirred for 20 hours at room temperature The solvent is then removed under reduced pressure and the residue is purified by chromatography on silica gel, eluting with the aid of a methanol / dichlorornethane mixture (4/96; v / v).
  • HMPA hexamethylphosphotriamide
  • Example 12 By following a procedure analogous to Example 2, starting from the compound obtained according to Example 12, the expected product is obtained in the form of a white solid with a yield of 88%.
  • Example 16 By following a procedure analogous to Example 2, starting from the compound obtained according to Example 16, the expected product is obtained in the form of a white solid with a yield of 76%.
  • the anti-atheromatous activity of the compounds according to the invention was evaluated as a function of their ability to lower the serum cholesterol level in mice subjected to a fatty diet. It has indeed been shown in several publications a close correlation between a lipid overload and a marked increase in the atheromatous risk (cf. Lancet 1996, 348 pages 1339-1342; Lancet 1990, 335 pages 1233-1235). This correlation makes it possible to implement a faster test than direct tests on the atheroma plate, said tests requiring a long treatment of animals and a heavy histological study of the walls of the aortic arch.
  • the test used consists in administering a single dose of the compound to female mice of strain C57BL / 6J.
  • the protocol is as follows: the first day (D0), the mice are fasted from 9 am to 5 pm, a blood sample being taken at 2 pm. At 5 p.m., a determined quantity of food (fatty diet comprising 1.25% cholesterol and 0.5% cholic acid) is distributed. On the second day (Jl), at 9 am, the food remains are weighed and the mice fasted from 9 am to 2 pm. At 2 p.m., a blood sample is taken. For groups of treated mice, the compound is administered by tubing, in suspension in a gummy water solution, at 3%, the second day (Jl) at 9 am. Control groups receive only gummy water.
  • the compounds were tested at a dose of 100 mg / kg.
  • the total serum cholesterol is assayed and the results are expressed as a percentage of inhibition of the increase in cholesterolemia compared to the control group.
  • the results obtained are reported in the "Activity" column of Table I.
  • the analysis of the cholesterol content of the various classes of serum lipoproteins shows a favorable effect of the product on the HDL-cholesterol / total cholesterol ratio. .
  • the products of formula I and their esters according to the invention can be administered, preferably orally, in the form of tablets or capsules, each containing 20 to 500 mg of a compound of formula I or one of its esters as an active ingredient, in combination with excipients.
  • the dosage will be approximately 1 to 4 taken per day.
  • the products according to the invention are advantageously prescribed vis-à-vis the atheroma plaque, and in particular for the prevention or treatment of atheromatous risk.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00988884A 1999-12-23 2000-12-06 Benzophenonglycopyranosiden, herstellung und therapeutische verwendung Withdrawn EP1240176A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9916389A FR2802930B1 (fr) 1999-12-23 1999-12-23 Benzophenone glycopyranosides, preparation et utilisation en therapeutique
FR9916389 1999-12-23
PCT/FR2000/003419 WO2001047940A1 (fr) 1999-12-23 2000-12-06 Benzophenone glycopyranosides, preparation et utilisation en therapeutique

Publications (1)

Publication Number Publication Date
EP1240176A1 true EP1240176A1 (de) 2002-09-18

Family

ID=9553756

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00988884A Withdrawn EP1240176A1 (de) 1999-12-23 2000-12-06 Benzophenonglycopyranosiden, herstellung und therapeutische verwendung

Country Status (17)

Country Link
US (1) US20030100515A1 (de)
EP (1) EP1240176A1 (de)
JP (1) JP2003519157A (de)
KR (1) KR20020071000A (de)
AU (1) AU2523501A (de)
BR (1) BR0016533A (de)
CA (1) CA2395561A1 (de)
CZ (1) CZ20022200A3 (de)
FR (1) FR2802930B1 (de)
IL (1) IL150237A0 (de)
MX (1) MXPA02006339A (de)
NO (1) NO20023003D0 (de)
NZ (1) NZ519719A (de)
PL (1) PL355885A1 (de)
RU (1) RU2002116676A (de)
SK (1) SK9072002A3 (de)
WO (1) WO2001047940A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229495B2 (en) 2002-12-23 2007-06-12 Siltron Inc. Silicon wafer and method for producing silicon single crystal
KR101126851B1 (ko) * 2008-08-27 2012-03-23 삼성메디슨 주식회사 적응적 컬러 도플러 수행 방법 및 그를 위한 초음파 진단 시스템

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492830A1 (fr) * 1980-10-29 1982-04-30 Sori Soc Rech Ind Nouveaux composes appartenant a la famille des benzoyl- et a-hydroxybenzyl-phenyl-osides, leur procede de preparation et leur application en therapeutique
FI92189C (fi) * 1986-03-17 1994-10-10 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisen difenyylimetaanijohdannaisen valmistamiseksi

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0147940A1 *

Also Published As

Publication number Publication date
KR20020071000A (ko) 2002-09-11
PL355885A1 (en) 2004-05-31
NO20023003L (no) 2002-06-21
NZ519719A (en) 2005-04-29
MXPA02006339A (es) 2002-12-13
CZ20022200A3 (cs) 2002-10-16
AU2523501A (en) 2001-07-09
IL150237A0 (en) 2002-12-01
FR2802930B1 (fr) 2003-10-10
RU2002116676A (ru) 2004-01-10
JP2003519157A (ja) 2003-06-17
FR2802930A1 (fr) 2001-06-29
SK9072002A3 (en) 2002-12-03
BR0016533A (pt) 2002-09-24
CA2395561A1 (en) 2001-07-05
US20030100515A1 (en) 2003-05-29
NO20023003D0 (no) 2002-06-21
WO2001047940A1 (fr) 2001-07-05

Similar Documents

Publication Publication Date Title
EP0051023B1 (de) Derivate der Benzoyl- und alpha-Hydroxybenzyl-phenyl-osid-Familie, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
EP0290321B1 (de) Beta-D-Phenyl-Thioxyloside, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
EP0133103B1 (de) Benzyl-Phenyl-Oside, Verfahren zur Herstellung und Verwendung
EP0421829B1 (de) Benzopyranon-beta-D-thioxyloside, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
EP1090017B1 (de) Alpha-d-xylose verbindungen, herstellung und verwendung als arzneimitteln
EP1240176A1 (de) Benzophenonglycopyranosiden, herstellung und therapeutische verwendung
EP1240177B1 (de) Benzophenon alpha-glycopyranoside, herstellung und therapeutische verwendung
FR2900405A1 (fr) Nouveaux composes c-glycosides monofluores, leurs procedes de preparation et leurs applications
EP1230252B1 (de) Beta-d-thioxylos-derivate, verfahren zur herstellung und verwendung als arzneimittel
EP1252171B1 (de) Verfahren zur herstellung von funktionalisierten beta-(1,3)-glucanderivaten
US20030139349A1 (en) Benzophenone alpha-d-glycopyranosides, preparation and therapeutic use
FR2826367A1 (fr) Nouveaux derives de [4-(4-cyanobenzoyl)phenyl] glycopyranoside, utilisation en tant que medicamment, procede d'obtention et compositions pharmaceutiques les contenant
FR2826368A1 (fr) Nouveaux derives de [4-(4-cyanobenzoyl)phenyl] glycofuranoside, utilisation en tant que medicamment, procede d'obtention et compositions pharmaceutiques les contenant
FR2472577A1 (fr) Nouveaux derives de l'acide aminobenzoique
LU85864A1 (fr) Nouveaux derives du bornane,leur preparation et compositions therapeutiques en contenant
EP0019524A1 (de) Verfahren zur Herstellung von Flavilliumderivaten, nach diesem Verfahren erhaltene Produkte und ihre therapeutische Anwendung
FR2804433A1 (fr) Derives de 4 -amino-4,6 -didesoxy- alpha d-glucopyranosyl- (1->4) - alpha-d-glucopyranosyl- (1->4) - alpha-d-glucopyran ose n-substitues et leur methode de preparation
WO2010067008A2 (fr) Derives bicycliques de morphine-6-glucuronide, leur preparation et leur application en therapeutique
BE857917A (fr) Nouveaux derives de la piperidine, leur preparation et leur application comme medicaments
BE860497A (fr) Esters d'acides 4-alkylaminobenzoiques, leur preparation et leurs utilisations therapeutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020613

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020613;LT PAYMENT 20020613;LV PAYMENT 20020613;MK PAYMENT 20020613;RO PAYMENT 20020613;SI PAYMENT 20020613

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LABORATOIRES FOURNIER S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040701